Who Paid My Doc
Luke Schwartz
Dentist, General Practice Washington, DC Doctor of Dentistry
NPI 1235583535 CMS profile 5695482
4801 Wisconsin Ave Nw Ste 200, Washington, DC 20016
General payments
$1,376
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Luke Schwartz of Washington, DC is reported in the CMS Open Payments database as having received $1,376 across 24 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 86th percentile of Dentist, General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $46 | 3 | |
| 2022 | General | $362 | 2 | |
| 2021 | General | $125 | 3 | |
| 2020 | General | $675 | 11 | |
| 2019 | General | $168 | 5 |
Beside peers
- Luke Schwartz
- Dentist, General Practice median
- Middle half of Dentist, General Practice
- National median
In program year 2025, general payments to Luke Schwartz were reported at $46. Among 41,122 Dentist, General Practice profiles paid that year, the median was $75 and the middle half received between $27 and $200.
Show as a table
| Year | Luke Schwartz | Dentist, General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $168 | $61 | $23–$158 | $163 |
| 2020 | $675 | $73 | $24–$142 | $114 |
| 2021 | $125 | $75 | $25–$184 | $132 |
| 2022 | $362 | $75 | $27–$198 | $149 |
| 2023 | $0 | $77 | $28–$200 | $160 |
| 2024 | $0 | $74 | $27–$187 | $164 |
| 2025 | $46 | $75 | $27–$200 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
11
Drug cost
$284
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Sodium Fluoride Fluoride (Sodium) | Brand | 11 | $284 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 110,731 Part D prescribers listed as Dentist; they describe a distribution and say nothing about conduct.
Records
24 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Dentist, General Practice in District of Columbia
Brian Gray
Dentist, General Practice · Washington, DC
Fahad Ashraf
Dentist, General Practice · Washington, DC
Shila Yazdani
Dentist, General Practice · Washington, DC
Roman Moss
Dentist, General Practice · Washington, DC
John Tsaknis
Dentist, General Practice · Washington, DC
Sheila Samaddar
Dentist, General Practice · Washington, DC
Related records
Dentist, General Practice in District of Columbia
Practitioners in the same specialty and state, ranked by reported value.
All Dentist, General Practice
Everyone recorded under this specialty, nationwide.
Doctors in District of Columbia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.